MREO · Mereo Biopharma Group Plc ADR
United States · RS rating 32 · As of 2026-11-03
| Price | 0.29 USD |
|---|---|
| 1-day change | +0.3% |
| RS rating (overall / 1M / 3M / 12M) | 32 / 16 / 57 / 7 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 16 / 9 / 23 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +87.4% |
| Market cap (USD) | $48.9M |